Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and effectiveness of lenalidomide
(Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE). The study drug will be used
in an off-label indication to treat 6 subjects for 12 months each. Men and women over the age
of 18, who have a biopsy proven diagnosis of CLE and who have failed standard treatment, will
be included in the study.